|
Dallas–Fort Worth, TX Press Releases
|
(Dallas.CityRegions.Com, March 20, 2015 ) Dallas, TX -- Cancer occurs when, after cell transformation, normal cells grow and multiply without control. Lung cancer is a common cause of mortality and morbidity in developed and developing countries. Smoking is considered to be the major cause of small cell lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two types: non-small cell lung cancer and small cell lung cancer. Small cell lung cancer constitutes roughly 10-15 percent of all diagnosed cases of lung cancer. Small cell lung cancer is categorized into two types: small cell carcinoma and combined small cell carcinoma. It can be further classified into two stages: limited-stage small cell lung cancer and extensive-stage small cell lung cancer. Small cell lung cancer is caused by smoking tobacco, or second hand smoking, or on exposure to asbestos, chromium, arsenic, nickel, soot, or radon. The common symptoms associated with lung cancer are chest pain, incurable cough, blood in sputum, fatigue, loss of appetite, unintentional weight loss, shortness of breath, and wheezing. Small cell lung cancer has a poor prognosis and gets diagnosed only at the late stage of disease progression, and hence, has a high mortality rate. There are no therapies available to cure small cell lung cancer in the market.
Analysts forecast the Global Small Cell Lung Cancer Therapeutics market to grow at a CAGR of 3.60 percent over the period 2014-2019.
Covered in this Report
Global Small Cell Lung Cancer Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Small Cell Lung Cancer Therapeutics market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Buy Report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=314539
Key Regions
Americas
APAC
EMEA
Key Vendors
Bristol-Myers Squibb
GlaxoSmithKline
Menarini
Sanofi
ZIOPHARM Oncology
Inquire before Buying @ http://www.rnrmarketresearch.com/contacts/inquire-before-buying?rname=314539 .
Other Prominent Vendors
Alchemia
Amgen
Apotex
BioMarin Pharmaceutical
CellAct Pharma
Cerulean Pharma
Cipla
Cornerstone Pharmaceuticals
Curis
CytRx
Eli Lilly
Exelixis
Fresenius Kabi
Genentech
Hikma Pharmaceuticals
Hospira
Intas Pharmaceuticals
Karyopharm Therapeutics
Kyowa Hakko Kirin
Ligand Pharmaceuticals
Lundbeck
MabVax Therapeutics Holdings
Medac Pharma
MEI Pharma
Merck
MolMed
Mologen
Mylan
Nektar Therapeutics
Neotropix
Novartis
Novogen
OncoMed Pharmaceuticals
Ono Pharmaceutical
PharmaMar
Polaris Group
Sagent Pharmaceuticals
Shanghai Jinhe Bio-Technology
Spectrum Pharmaceuticals
STADA Arzneimittel
Stem CentRx
Sun Pharmaceuticals Industries
Takeda Pharmaceutical
Teva Pharmaceutical
Zydus Cadila Healthcare
Market Driver
High Unmet Need
Market Challenge
High Cost of Treatment
Market Trend
Strategic Alliances
Key Questions Answered in this Report
What will the market size be in 2019 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?
Inquire for Discount @ http://www.rnrmarketresearch.com/contacts/discount?rname=314539 .
About Us:
RnRMarketResearch.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.
Public Safety LTE & Mobile Broadband Market
RnR Market Research
Ritesh Tiwari
1 888 391 5441
sales@rnrmarketresearch.com
Source: EmailWire.Com
|
|
|
|